LivaNova (NASDAQ:LIVN) Stock Price Up 4.2%

LivaNova PLC (NASDAQ:LIVN) rose 4.2% on Wednesday . The stock traded as high as $50.22 and last traded at $48.54. Approximately 766,364 shares changed hands during trading, an increase of 15% from the average daily volume of 663,843 shares. The stock had previously closed at $46.60.

Wall Street Analysts Forecast Growth

LIVN has been the topic of several recent research reports. Needham & Company LLC increased their price target on LivaNova from $72.00 to $75.00 and gave the company a “buy” rating in a report on Wednesday, July 31st. Robert W. Baird restated a “neutral” rating and issued a $55.00 target price on shares of LivaNova in a report on Wednesday. Stifel Nicolaus lifted their price target on shares of LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Finally, Mizuho increased their price objective on shares of LivaNova from $75.00 to $80.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $65.83.

LivaNova Stock Up 0.3 %

The company has a market cap of $2.73 billion, a PE ratio of -83.98 and a beta of 0.99. The company’s 50 day moving average is $50.02 and its 200 day moving average is $53.84. The company has a current ratio of 3.45, a quick ratio of 2.71 and a debt-to-equity ratio of 0.49.

Insiders Place Their Bets

In other LivaNova news, Director Daniel Jeffrey Moore sold 56,623 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $60.11, for a total transaction of $3,403,608.53. Following the transaction, the director now directly owns 27,534 shares in the company, valued at approximately $1,655,068.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets boosted its position in LivaNova by 98.3% during the 4th quarter. BNP Paribas Financial Markets now owns 22,338 shares of the company’s stock valued at $1,156,000 after acquiring an additional 11,075 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in LivaNova by 6.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,241,985 shares of the company’s stock valued at $64,262,000 after purchasing an additional 74,067 shares in the last quarter. Principal Financial Group Inc. grew its stake in LivaNova by 2.4% in the fourth quarter. Principal Financial Group Inc. now owns 225,385 shares of the company’s stock valued at $11,661,000 after purchasing an additional 5,329 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its holdings in LivaNova by 34.6% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 5,521 shares of the company’s stock worth $286,000 after purchasing an additional 1,418 shares in the last quarter. Finally, Panagora Asset Management Inc. lifted its position in shares of LivaNova by 183.7% during the fourth quarter. Panagora Asset Management Inc. now owns 157,899 shares of the company’s stock valued at $8,170,000 after buying an additional 102,235 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.